イオパミドール含有シスプラチン・エピルビシン・リピオドール・エマルジョン(CELE)による肝細胞癌動注化学療法の検討

概要

論文の詳細を見る
The clinical evaluation (i. e., survival rate of patients) and pharmaceutical characteristics of CELE for HCC were examined. Using image analyzer or scanning electron microscope with cryosystem, it appeared that CELE were maintained emulsion for 24 hours after preparation. In metalic ion elution test from vial or syringe including CELE, a few metalic ions were detected. In a bacteriological examination, CELE was a germ-free. In rat mesentery artery preparation, CELE was passed through the artery smoothly. For tumor stages II, III, and IV, 1-, 2- and 3-years survival values were 90%, 67% and 67%, respectively (treatment with CELE arterial injection and transcatheter arterial embolization), while for tumor stage II, 1-, 2-years survival values were 59% and 27%, respectively (CELE arterial injection only). No severe side effects were observed with CELE. A combination treatment of HCC appears to be more effective.